» Articles » PMID: 30386797

Micropulse Transscleral Cyclophotocoagulation: A Hypothesis for the Ideal Parameters

Overview
Specialty Ophthalmology
Date 2018 Nov 3
PMID 30386797
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

MicroPulse transscleral cyclophotocoagulation (IRIDEX Corp., Mountain View, CA) is a novel technique that uses repetitive micropulses of active diode laser (On cycles) interspersed with resting intervals (Off cycles). It has been proposed that the OFF cycles allow thermal dissipation and, therefore, reduce collateral damage. The literature suggests that Micropulse has a better safety profile compared to traditional continuous-wave cyclophotocoagulation. However, because it is a relatively new technique, there are no clear guidelines stating the ideal laser parameters that would allow the best balance between high and sustained effectiveness with minimal side effects. This research reviewed the literature to approximate ideal parameters for single-session treatment. To simplify the comparison between studies, this study used Joules (J) as a way to standardize the energy levels employed. The reviewed clinical publications allowed reduction of these parameters to a range between 112 and 150 J of total energy, which allows a moderate IOP lowering effect of around 30% with few/no complications. An additional narrowing of the parameters was achieved after analyzing recently published experimental data. These data suggest a different mechanism of action for the Micropulse, similar to that of the pilocarpine. This effect was maximum at 150 J. Since clinical studies show few or no complications, even at those energy levels, it could be hypothesized that the ideal parameters can be located at a point closer to 150 J. This data also leads to the concept of dosimetry; the capacity to dose mTSCPC treatment based on desired IOP lowering effect and risk exposure. Further prospective studies are needed to test the proposed evidence-based hypothesis.

Citing Articles

MicroPulse Transscleral Laser Therapy: A Retrospective Study of Dose Efficacy and Safety.

Nguyen J, Gonzalez-Martinez O, Khouri A J Curr Glaucoma Pract. 2024; 18(3):121-129.

PMID: 39575126 PMC: 11576340. DOI: 10.5005/jp-journals-10078-1450.


The effect of cumulative energy in repeated subliminal transscleral cyclophotocoagulation: a retrospective study.

Szabo A, Arpadffy-Lovas T, Hagyo K, Cseke I, Vamosi P, Toth-Molnar E BMC Ophthalmol. 2024; 24(1):233.

PMID: 38831268 PMC: 11145849. DOI: 10.1186/s12886-024-03505-7.


Micropulse Transscleral Cyclophotocoagulation in Non-Incisional Eyes with Ocular Hypertension and Primary Open-Angle Glaucoma.

Murtaza F, Kaba Q, Somani S, Tam E, Yuen D Clin Ophthalmol. 2024; 18:1295-1312.

PMID: 38751993 PMC: 11095520. DOI: 10.2147/OPTH.S447875.


Clinical Outcomes of MicroPulse Transscleral Laser Therapy with the Revised P3 Delivery Device.

Checo L, Dorairaj S, Wagner I, Ahuja A J Curr Glaucoma Pract. 2024; 18(1):10-15.

PMID: 38585165 PMC: 10997959. DOI: 10.5005/jp-journals-10078-1427.


Evaluation of laser power stability of repeatedly used SubCyclo probe in micropulse transscleral cyclophotocoagulation for glaucoma: A step towards sustainable ophthalmic surgery.

Suvannachart P, Rujkorakarn P, Watha T, Srihatrai P PLoS One. 2023; 18(12):e0295517.

PMID: 38064479 PMC: 10707564. DOI: 10.1371/journal.pone.0295517.


References
1.
Kosoko O, Gaasterland D, POLLACK I, Enger C . Long-term outcome of initial ciliary ablation with contact diode laser transscleral cyclophotocoagulation for severe glaucoma. The Diode Laser Ciliary Ablation Study Group. Ophthalmology. 1996; 103(8):1294-302. DOI: 10.1016/s0161-6420(96)30508-3. View

2.
Sanchez F, Lerner F, Sampaolesi J, Noecker R, Becerra N, Iribarren G . Efficacy and Safety of Micropulse® Transscleral Cyclophotocoagulation in Glaucoma. Arch Soc Esp Oftalmol (Engl Ed). 2018; 93(12):573-579. DOI: 10.1016/j.oftal.2018.08.003. View

3.
Aquino M, Barton K, Tan A, Sng C, Li X, Loon S . Micropulse versus continuous wave transscleral diode cyclophotocoagulation in refractory glaucoma: a randomized exploratory study. Clin Exp Ophthalmol. 2014; 43(1):40-6. DOI: 10.1111/ceo.12360. View

4.
Malvankar-Mehta M, Chen Y, Iordanous Y, Wang W, Costella J, Hutnik C . iStent as a Solo Procedure for Glaucoma Patients: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(5):e0128146. PMC: 4446040. DOI: 10.1371/journal.pone.0128146. View

5.
Quigley H, Broman A . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-7. PMC: 1856963. DOI: 10.1136/bjo.2005.081224. View